Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on US Healthcare Journal.
Press releases published on March 20, 2025
Cannabis Access Expands in Washington, NJ with Diverse Product Selection from Dank Poet Weed Dispensary
EIN Presswire
·
March 20, 2025
Dank Poet Weed Dispensary provides a range of cannabis brands and purchasing options for consumers in Washington, NJ WASHINGTON, NJ, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- As the cannabis industry continues to evolve, access to regulated …
Menarini Group Announces Collaboration with VisualDx to Aid in Identifying People Who May Have Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
GlobeNewswire
·
March 20, 2025
BPDCN is an aggressive hematologic malignancy with a historically poor prognosis VisualDx is a clinical decision support system used by more than 2,300 hospitals, clinics, and medical schools around the world VisualDx’s system seeks to enhance …
TOMI Environmental Solutions Selected by NASA for Biosecurity Operation
GlobeNewswire
·
March 20, 2025
FREDERICK, Md., March 20, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions developed through DARPA technology, today announced the deployment of its …
Autonomix Medical, Inc. Granted U.S. Patent Covering Sensing Data Collection and Processing with Company’s Proprietary Catheter-Based Technology
GlobeNewswire
·
March 20, 2025
Continued progress with growing global patent portfolio to over 80 issued patents and 40 pending patent applications Proprietary sensing and ablation technology has demonstrated potential to more precisely target and eliminate overactive nerves, improving …
Dyadic Announces Funding Award from CEPI to Use C1 to Accelerate Development of Protein-Based Vaccines
GlobeNewswire
·
March 20, 2025
JUPITER, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal …
Wound Care Pioneer, Gentell’s David Navazio, To Receive 2025 Baldrige Foundation Award for Leadership Excellence
EIN Presswire
·
March 20, 2025
David Navazio has been selected to receive the 2025 Baldrige Foundation Award for Leadership Excellence for his accomplishments in health care. NEWTOWN, PA, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- The Malcolm Baldrige Foundation has …
STRATA Skin Sciences Highlights New Clinical Study from Japan Demonstrating Superiority of Narrow Band Excimer Laser Over Non Narrow Band UVB-Source Like Excimer Light
GlobeNewswire
·
March 20, 2025
HORSHAM, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues
GlobeNewswire
·
March 20, 2025
CARMEL, Ind., March 20, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, …
CorVista Health to Present New Data on Non-Invasive Point of Care Test for Pulmonary Capillary Wedge Pressure Elevation Using Machine Learning at ACC.25
GlobeNewswire
·
March 20, 2025
BETHESDA, Md., March 20, 2025 (GLOBE NEWSWIRE) -- CorVista Health today announced the upcoming poster presentation of new data on its non-invasive point of care test for pulmonary capillary wedge pressure (PCWP) elevation – a key indicator of heart failure …
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
GlobeNewswire
·
March 20, 2025
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the …
Invivyd Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Recent Business Highlights
GlobeNewswire
·
March 20, 2025
Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 million 2024 year-end cash and cash equivalents of $69. …
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia
GlobeNewswire
·
March 20, 2025
– Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure …
Nitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease
GlobeNewswire
·
March 20, 2025
- Glyoxalase Domain-containing Protein 4 (GLOD4), the First Identified in a New Class of Enzymes Called Nitrases, Generates Nitrated Alpha-synuclein, a Hallmark of Parkinson’s Disease (PD) -Company Advancing Both NDC-0524, a Monoclonal Antibody with High …
Medera Receives DSMB Clearance to Initiate Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial for SRD-001 Gene Therapy in Heart Failure with Reduced Ejection Fraction
GlobeNewswire
·
March 20, 2025
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on cardiovascular diseases with high unmet need by developing a range of next-generation therapeutics, today announced that the …
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
GlobeNewswire
·
March 20, 2025
SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for …
Reflect Scientific Inc. Reports Strong Revenue Growth in 2024
GlobeNewswire
·
March 20, 2025
OREM, Utah, March 20, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (OTC: RSCF), a leading provider of cryogenic cooling and laboratory equipment, is pleased to announce a significant increase in revenue for the fiscal year ending December 31, 2024. …
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
GlobeNewswire
·
March 20, 2025
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, …
Pathos AI Doses First Patient in Phase 1b/2a Clinical Trial of Pocenbrodib, a CBP/p300 Inhibitor
GlobeNewswire
·
March 20, 2025
CHICAGO, March 20, 2025 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, announced the first patient has been dosed in the Company’s Phase 1b …
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
GlobeNewswire
·
March 20, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic …
Creative Medical Technology Holdings Secures FDA Clearance for Expanded Dose Escalation in the Clinical Trial of CELZ-201-DDT for Chronic Lower Back Pain
GlobeNewswire
·
March 20, 2025
PHOENIX, March 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that the U.S. Food and Drug Administration …